Polaroid Therapeutics designed POLTX_Fibers™ to help reduce infection risk while supporting wound healing at the point of care.
The approval from the Medicines and Healthcare products Regulatory Agency (MHRA) marks another milestone in the rapidly growing market for oral weight-loss medicines.
Anaphylaxis occurs when the immune system overreacts to a substance it perceives as harmful, triggering symptoms that can rapidly become life-threatening.
The approval specifically applies to adults diagnosed with obesity and does not extend to individuals who are overweight with a BMI below 30kg/m² using Wegovy for weight management.
Since launching in 2024, AI Airlock has grown steadily, moving beyond its initial pilot phase to tackle increasingly complex regulatory questions.
Adults with obesity and a BMI of 30 kg/m² or higher can now use Wegovy at a 7.2mg dose level, which requires three consecutive 2.4mg doses instead of a single injection.
With this latest authorisation, individuals now have access to a long-acting option for prevention rather than daily pill-based regimens.
This oral formulation offers a more convenient delivery method compared to intravenous treatments.